Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

453P - QUAlity of LIfe and survival of meTAStatic colorectal cancer patients treated with trifluridine-tipiracil (QUALITAS)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Patricia Hamers

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

P. Hamers1, G. Vink2, M. Elferink3, M. Koopman4, A.M. May5

Author affiliations

  • 1 Medical Oncology, UMC - University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 2 Medical Oncology, UMC-University Medical Center Utrecht, 3584 CX - Utrecht/NL
  • 3 Department Of Research And Development, Netherlands Comprehensive Cancer Organisation, 3511DT - Utrecht/NL
  • 4 Medical Oncology Dept, University Medical Center Utrecht, 3508 GA - Utrecht/NL
  • 5 Julius Center, UMC-University Medical Center Utrecht, 3584 CX - Utrecht/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 453P

Background

In metastatic colorectal cancer (mCRC), the main aim of treatment is to prolong overall survival (OS) without impairing quality of life (QoL). The RECOURSE trial demonstrated that trifluridine/tipiracil (FTD/TPI) significantly improved OS versus placebo in pretreated mCRC patients. QoL was not assessed in this phase III trial.

Methods

From 497 mCRC patients who were treated with FTD/TPI, clinical data was obtained from the population-based Netherlands Cancer Registry. From 169 patients, additional QoL (EORTC QLQ-C30) data was collected monthly from start of FTD/TPI in the QUALITAS cohort, a substudy of the Prospective Dutch CRC cohort (PLCRC). We calculated the QLQ-C30 Summary Score (QoL-SS). Differences in scores were deemed clinically relevant if ≥10 points.

Results

Median time on FTD/TPI treatment of the complete cohort (n=497) was 2.7 months (IQR 1.8-3.8). Median time from mCRC diagnosis to start FTD/TPI was 17.7 months (IQR 11.5-27.9). Median OS from initiation of FTD/TPI was 5.1 months (95% CI 4.6-5.6). To date, QoL results are available for 68 patients. Results of the total cohort will follow in the next 3 months. Patients who were treated with FTD/TPI for at least 3 months (n=24) reported clinically relevant less fatigue, appetite loss and higher QoL at treatment start than patients with shorter treatment duration (n=44): 28.2±20.2 vs. 46.6±27.5 (p=0.003), 4.2±14.9 vs. 31.1±36.2 (p<0.0001), and 84.4±10.3 vs. 74.8±18.1 (p=0.007), respectively. In the total group, no clinically relevant deterioration of QoL during FTD/TPI treatment was observed. QoL-SS at baseline was 78.3±16.3, after 2 months of treatment 80.8±14.6, after 3 months 84.3±13.8, and after 4 months 80.4±17.3. Also, fatigue, appetite loss, and nausea/vomiting did not deteriorate over time. Final QoL results will be presented at the ESMO Congress.

Conclusions

Overall survival in almost 500 patients from start of FTD/TPI is comparable to other population-based studies. Our results suggest that fewer symptoms at start of FTD/TPI treatment are associated with longer treatment duration. QoL was maintained during FTD/TPI treatment, which supports its use in clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Servier Nederland Farma BV.

Disclosure

G. Vink: Research grant/Funding (institution), Travel/Accommodation/Expenses: Servier Farma; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Merck. M. Koopman: Honoraria (institution), Research grant/Funding (institution): BMS; Honoraria (institution), Research grant/Funding (institution): Nordic Pharma; Honoraria (institution), Research grant/Funding (institution): Servier Farma; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Merck-Serono; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Sirtex; Research grant/Funding (institution): Sanofi-Aventis; Travel/Accommodation/Expenses: Congress-Care - Dutch oncology society (NVMO). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.